Outcomes and prognostic factors of patients with Extranodal NK T cell lymphoma (ENKTL)

References

• Au Wy, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the international peripheral T-Cell lymphoma project. Blood. 2009;113(17):3931–3937. doi:10.1182/blood-2008-10-185256
   PubMed Web of Science ®Google Scholar
• Yoon SE, Song Y, Kim SJ, Yoon DH, Chen TY, Koh Y, et al. Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. Lancet Reg Health - West Pac. 2021 May 1;10:100126.
   Google Scholar
• Vose JM, Neumann M, Harris ME. International peripheral T-Cell and natural killer/T-Cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Cheung MMC, Chan JKC, Wong KF. Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias. Semin Hematol. 2003;40(3):221–232. doi:10.1016/s0037-1963(03)00136-7
   PubMed Web of Science ®Google Scholar
• Kim TM, Park YH, Lee SY, et al. Local tumor invasiveness is more predictive of survival than international prognostic index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood. 2005;106(12):3785–3790. doi:10.1182/blood-2005-05-2056
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24(4):612–618. doi:10.1200/JCO.2005.04.1384
   PubMed Web of Science ®Google Scholar
• Lin T, Hong H, Liang C, et al. Extranodal natural killer T-cell lymphoma, nasal-type—a new staging system from CSWOG—a multicenter study. J Clin Oncol. 2014;32(15_suppl):8552–8552. doi:10.1200/jco.2014.32.15_suppl.8552
   Web of Science ®Google Scholar
• Yan Z, Huang HQ, Wang XX, et al. A TNM staging system for nasal NK/T-Cell lymphoma. PLoS One. 2015;10(6):e0130984. doi:10.1371/journal.pone.0130984
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–2479. doi:10.1182/blood-2003-09-3080
   PubMed Web of Science ®Google Scholar
• Lee J, Park YH, Kim WS, et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer. 2005;41(10):1402–1408. doi:10.1016/j.ejca.2005.03.010
   PubMed Web of Science ®Google Scholar
• Kim K, Kim WS, Jung CW, et al. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the revised European-American lymphoma (REAL) classification. Eur J Cancer. 2002;38(1):75–81. doi:10.1016/s0959-8049(01)00344-6
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(3):389–400. doi:10.1016/S1470-2045(15)00533-1
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76(11):2351–2356. doi:10.1002/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1
   PubMed Web of Science ®Google Scholar
• Ke QH, Zhou SQ, Du W, et al. Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell lymphoma. Blood Cancer J. 2014;4(12):e267. doi:10.1038/bcj.2014.88
   PubMedGoogle Scholar
• Jiang M, Zhang H, Jiang Y, et al. Phase 2 trial of “sandwich” L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer. 2012;118(13):3294–3301. doi:10.1002/cncr.26629
   PubMed Web of Science ®Google Scholar
• Zhang L, Jiang M, Xie L, et al. Five-year analysis from phase 2 trial of “sandwich” chemoradiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer Med. 2016;5(1):33–40. doi:10.1002/cam4.569
   PubMed Web of Science ®Google Scholar
• Jiang M, Zhang L, Xie L, et al. A phase II prospective study of the “sandwich” protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma. Oncotarget. 2017;8(30):50155–50163. doi:10.18632/oncotarget.16334
   PubMedGoogle Scholar
• Huang Y, Yang J, Liu P, et al. Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2017;96(9):1477–1483. doi:10.1007/s00277-017-3046-2
   PubMed Web of Science ®Google Scholar
• Wang L, Wang Zh, Chen X Q, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013;119(2):348–355. doi:10.1002/cncr.27752
   PubMed Web of Science ®Google Scholar
• Wei W, Wu P, Li L, et al. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma. Hematology. 2017;22(6):320–329. doi:10.1080/10245332.2016.1264163
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-Cell lymphoma: Japan clinical oncology group study JCOG0211. J Clin Oncol. 2009;27(33):5594–5600. doi:10.1200/JCO.2009.23.8295
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Tobinai K, Oguchi M, et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol. 2012;30(32):4044–4046. doi:10.1200/JCO.2012.45.6541
   PubMed Web of Science ®Google Scholar
• Tsai HJ, Lin SF, Chen CC, et al. Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma. Eur J Haematol. 2015;94(2):130–137. doi:10.1111/ejh.12405
   PubMed Web of Science ®Google Scholar
• Michot JM, Mazeron R, Danu A, et al. Concurrent etoposide, steroid, high-dose Ara-C and platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. Eur J Cancer. 2015;51(16):2386–2395. doi:10.1016/j.ejca.2015.07.009
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol. 2009;27(35):6027–6032. doi:10.1200/JCO.2009.23.8592
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yang DH, Kim JS, et al. Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol. 2014;93(11):1895–1901. doi:10.1007/s00277-014-2137-6
   PubMed Web of Science ®Google Scholar
• Yoon DH, Kim SJ, Jeong SH, et al. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). Oncotarget. 2016;7(51):85584–85591. doi:10.18632/oncotarget.11319
   PubMed Web of Science ®Google Scholar
• Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117(6):1834–1839. doi:10.1182/blood-2010-09-307454
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-Cell lymphoma, nasal type: the NK-Cell tumor study group study. J Clin Oncol. 2011;29(33):4410–4416. doi:10.1200/JCO.2011.35.6287
   PubMed Web of Science ®Google Scholar
• Ding H, Chang J, Liu LG, et al. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study. Int J Hematol. 2015;102(2):181–187. doi:10.1007/s12185-015-1809-x
   PubMed Web of Science ®Google Scholar
• Wang JH, Wang L, Liu CC, et al. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma. Oncotarget. 2016;7(20):29092–29101. doi:10.18632/oncotarget.8647
   PubMedGoogle Scholar
• Wang J J, Dong M, He Xh, et al. GDP (gemcitabine, dexamethasone, and cisplatin) is highly effective and Well-Tolerated for newly diagnosed stage IV and relapsed/refractory extranodal natural killer/T-Cell lymphoma, nasal type. Medicine (Baltimore). 2016;95(6):e2787. doi:10.1097/MD.0000000000002787
   PubMed Web of Science ®Google Scholar
• Li X, Cui Y, Sun Z, et al. DDGP versus SMILE in newly diagnosed advanced natural killer/T-Cell lymphoma: a randomized controlled, multicenter, open-label study in China. Clin Cancer Res. 2016;22(21):5223–5228. doi:10.1158/1078-0432.CCR-16-0153
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang L, Liu X, et al. Efficacy and safety of a Pegasparaginase-Based chemotherapy regimen vs an L-asparaginase–based chemotherapy regimen for newly diagnosed advanced extranodal natural killer/T-Cell lymphoma: a randomized clinical trial. JAMA Oncol. 2022;8(7):1035–1041. doi:10.1001/jamaoncol.2022.1968
   PubMed Web of Science ®Google Scholar
• Burad DK, Therese MM, Nair S. Peripheral T-cell lymphoma: frequency and distribution in a tertiary referral center in South India. Indian J Pathol Microbiol. 2012;55(4):429–432. doi:10.4103/0377-4929.107770
   PubMed Web of Science ®Google Scholar
• Naresh KN, Agarwal B, Nathwani BN, et al. Use of the world health organization (WHO) classification of Non-Hodgkin’s lymphoma in mumbai, India: a review of 200 consecutive cases by a panel of five expert hematopathologists. Leuk Lymphoma. 2004;45(8):1569–1577. doi:10.1080/10428190410001683679
   PubMed Web of Science ®Google Scholar
• Saldanha SC, Babu KG, Lokanatha D, Jacob LA, Babu MCS, Lokesh KN, et al. Extranodal NK/T cell lymphoma- nasal type: Experience from an Indian regional cancer centre. Ann Oncol. 2018 Nov 1;29:ix89–90.
   Google Scholar
• Bothra SJ, Bhandari P, Agrawal N, et al. Extranodal NK-T cell lymphoma, nasal type: retrospective analysis of Real-World data. Indian J Hematol Blood Transfus. 2020;36(2):260–266. Aprdoi:10.1007/s12288-019-01195-6
   PubMed Web of Science ®Google Scholar
• Arora N, Mehta A, Ravichandran S, et al. NK/T cell lymphoma: a tertiary Centre experience. Indian J Hematol Blood Transfus. 2017;33(1):69–73. Mardoi:10.1007/s12288-016-0675-x
   PubMed Web of Science ®Google Scholar
• Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009;2009(1):523–531. doi:10.1182/asheducation-2009.1.523
   Google Scholar
• Suzuki R, Takeuchi K, Ohshima K, et al. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol. 2008;26(2):66–72. doi:10.1002/hon.847
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–3068. doi:10.1200/JCO.2013.54.8800
   PubMed Web of Science ®Google Scholar
• Allen PB, Lechowicz MJ. Management of NK/T-Cell lymphoma, nasal type. J Oncol Pract. 2019;15(10):513–520. doi:10.1200/JOP.18.00719
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood. 2018;131(23):2528–2540. doi:10.1182/blood-2017-12-791418
   PubMed Web of Science ®Google Scholar
• Ghione P, Qi S, Imber BS, et al. Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population. Leuk Lymphoma. 2020;61(14):3331–3341. doi:10.1080/10428194.2020.1811864
   PubMed Web of Science ®Google Scholar
• Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the asia lymphoma study group. Blood. 2012;120(15):2973–2980. doi:10.1182/blood-2012-05-431460
   PubMed Web of Science ®Google Scholar
• Chen Y, Luo L, Zheng X, et al. Clinical characteristics and survival of extranodal natural killer/T-cell lymphoma: a single-center 12-year retrospective analysis. Leuk Lymphoma. 2020;61(14):3306–3318. doi:10.1080/10428194.2020.1808207
   PubMed Web of Science ®Google Scholar
• Vittayawacharin P, Khuhapinant A. A five-year retrospective study of treatment outcomes using the L-asparaginase-based regimen as a first-line chemotherapy protocol for patients diagnosed with extranodal NK/T-cell lymphoma, nasal-type, in Thailand. Hematology. 2021;26(1):75–82. doi:10.1080/16078454.2020.1867783
   PubMed Web of Science ®Google Scholar
• Li J, Li J, Zhong M, et al. The clinical features and survival outcome of 107 newly diagnosed advanced stage extranodal NK/T-Cell lymphoma cases: a Triple-Center study. Cancer Manag Res. 2021;13:1541–1549. doi:10.2147/CMAR.S292293
   PubMed Web of Science ®Google Scholar
• Qi S, Yahalom J, Hsu M, et al. Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population. Leuk Lymphoma. 2016;57(11):2575–2583. doi:10.1080/10428194.2016.1180689
   PubMed Web of Science ®Google Scholar
• Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus–DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011;118(23):6018–6022. doi:10.1182/blood-2011-05-354142
   PubMed Web of Science ®Google Scholar